Nuformix plc (NFX.L) Diversifiers

Equity · Currency in GBp · Last updated Jun 6, 2026

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.

Looking to balance out your exposure to NFX.L? The ETFs below have the lowest correlation with NFX.L — they tend to move on their own, which can help reduce risk when NFX.L drops. The stock ideas table highlights individual companies that behave independently from NFX.L.

No Diversifiers Found for NFX.L

We do not have enough correlation history to rank diversifiers for this symbol yet.

Diversification Analysis

Build a portfolio that complements NFX.L

Add NFX.L to the Diversification Analyzer to see how it overlaps with your other holdings and which assets balance it best.

Analyze a portfolio with NFX.L